| Catalog Number |
PR139481597 |
| CAS |
139481-59-7 |
| Structure |  |
| Description |
Candesartan is a benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an environmental contaminant and a xenobiotic. |
| Synonyms |
1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid |
| IUPAC Name |
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid |
| Molecular Weight |
440.5 |
| Molecular Formula |
C24H20N6O3 |
| InChI |
HTQMVQVXFRQIKW-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) |
| Drug Categories |
Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor antagonists; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzene Derivatives; Cardiovascular Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (weak); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (weak); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds, Fused-Ring; Lipid Modifying Agents; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; UGT1A3 substrates |
| Drug Interactions |
Abaloparatide-Abaloparatide may increase the hypotensive activities of Candesartan.
Abatacept-The metabolism of Candesartan can be increased when combined with Abatacept.
Abrocitinib-The metabolism of Abrocitinib can be decreased when combined with Candesartan.
Acebutolol-Acebutolol may increase the hypotensive activities of Candesartan.
Aceclofenac-The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Aceclofenac. |
| Isomeric SMILES |
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O |
| Type |
Small Molecule |
| Therapeutic Category |
Antihypertensive |
It should be noted that our service is only used for research, not for clinical use.
